Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | GRPR | P30550 | 2/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29310044 | 0.92 | PTPN1 (0.43) | PTPN1BACE1BACE2F2MMP2 | |
| SCHEMBL31094977 | 0.86 | PTPN1 (0.46) | PTPN1BACE1BACE2F2ERAP2 | |
| SCHEMBL3253193 | 0.83 | PTPN1 (0.43) | PTPN1BACE1BACE2F2CTNNB1 | |
| SCHEMBL30433903 | 0.82 | PTPN1 (0.47) | PTPN1BACE1BACE2EGFR | |
| SCHEMBL31746072 | 0.82 | PTPN1 (0.49) | PTPN1BACE1BACE2ERAP2GRPR | |
| SCHEMBL19051569 | 0.81 | GNPAT (0.40) | PTPN1BACE1BACE2ERAP2 | |
| SCHEMBL7599777 | 0.80 | ERAP2 (0.44) | PTPN1BACE1BACE2ERAP2 | |
| SCHEMBL31354582 | 0.80 | PTPN1 (0.44) | PTPN1BACE1BACE2EGFRERAP2 | |
| SCHEMBL7599791 | 0.80 | ERAP2 (0.44) | PTPN1BACE1BACE2ERAP2 | |
| SCHEMBL30632045 | 0.79 | MAGI3 (0.39) | PTPN1BACE1BACE2F2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229043-A1 | Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN | UNIV PENNSYLVANIA (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240229043-A1 | Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN | FASN, CASP9, AIFM2 | PTPN1 2992/4885BACE1 1016/4885BACE2 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.